110 results about "Angiotensin 2 Receptor Blocker" patented technology

The invention relates to the use of angiotensin II receptor antagonists for treating people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure.

The present invention relates to a bilayer pharmaceutical tablet comprising a first layer formulated for immediate release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix which contains telmisartan in substantially amorphous form, and a second layer formulated for immediate release of a diuretic like hydrochlorothiazide from a fast disintegrating tablet matrix. A method of producing the bilayer tablet is also disclosed.

The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; renin inhibitors and combinations thereof. Other aspects of the invention relate to a pharmaceutical composition containing a RAS suppressor and a progestogen and to a pharmaceutical kit having a plurality of dosage units, wherein at least one dosage unit contains a progestogen; at least one dosage unit contains an estrogen; and at least one dosage unit contains a RAS suppressor.

In one aspect, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of a dermatological disorder, particularly by topical application of said ACE inhibitor and/or angiotensin II receptor antagonist. The present invention also provides cosmetic methods for improving and/or maintaining the skin tone of an individual suffering from, or at risk of suffering from, a dermatological disorder, said method comprising contacting the skin of said individual with an ACE inhibitor and/or angiotensin II receptor antagonist.

The invention discloses a pharmaceutical composition for treating hypertension and other cardiovascular diseases, wherein the active constituents include pharmaceutical salts of levamlodipine besylate and angiotensin II receptor antagonists. The invention can not only overcome the drawback of photodecomposition of the levoamlodipine maleate medicaments, but also can increase the dissolving degree by 21%.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.

The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

The present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist of the preparation of a medicament for the treatment of skin ageing or wrinkling. Furthermore, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a cosmetic composition.

A pharmaceutical preparation comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from the group consisting of a hydrophilic polymer, an acidic substance and a fluidizing agent. The pharmaceutical preparation has improved dissolution properties.

The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.

The invention relates to the technical field of medicines, in particular to a telmisartan solid dispersion as a specific angiotensin II receptor antagonist (ATI type) and a preparation method thereof. The telmisartan solid dispersion comprises medicine telmisartan, a carrier and an alkali matter, and also comprises a surfactant, wherein the carrier is a hydrophilic polymeric carrier, and the mass ratio of the medicine telmisartan to the hydrophilic polymeric carrier to the alkali matter to the surfactant is 1:(1-9):(0.1-0.5):(0.1-0.5). The telmisartan solid dispersion has better dissolution rate during the use, and is convenient for gastrointestinal tract absorption, thereby improving bioavailability.

The invention relates to a pharmaceutical composition containing a calcium channel blocker (CCB) or the mixture thereof, an angiotonin 3II receptor blocker (ARB) or the mixture thereof, statins or the mixture thereof and a pharmaceutically acceptable carrier, wherein the CCB is selected from l-amlodipine, amlodipine, lacidipine, nitrendipine or the mixture thereof; the angiotonin II receptor blocker is selected from telmisartan, losartan, irbesartan, candesartan or the mixture thereof; and the statins are selected from atorvastatin, simvastatin, ruishufatadine, fluvastatin or the mixture thereof. The pharmaceutical composition is used for treating various high blood pressures and preventing or treating cardiovascular and cerebrovascular diseases relevant to the hypertension, reduces the disease rate and/or mortality rate of the cardiovascular and cerebrovascular diseases and also improves the adaptability for a sufferer taking medicine.

The present invention relates to a method of prophylaxis or treatment of systemic diseases in cats, wherein the method comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.

The invention relates to a sustained release preparation of a novel prescription for treating hypertension and the preparing method thereof. The novel prescription comprises a heart selective Beta1 receptor blocker metoprolol and an angiotensin II receptor antagonist (sartan drugs). The sustained release preparation consists of delayed release part and rapid release part, wherein the heart selective Beta1 receptor blocker metoprolol is the delayed release part, with first hour releasing 25-45%, fourth hour releasing 40-75% and eighth hour releasing over 75%; the angiotensin II receptor antagonist (sartan drugs) is the rapid release part, with 45 minutes dissolution over 75%. The composition has both rapid and prolonged action. The invention discloses in vitro drug release characteristics and preparation method thereof.

The invention relates to application of telmisartan and aliskiren or medicinal salts thereof in preparing a combined medicament for treating hypertension. The invention also provides the combined medicament for treating hypertension, wherein the combined medicament contains unit preparations of different specifications, and the preparations administrated simultaneously, respectively or in turn are prepared from telmisartan and aliskiren or medicinal salts thereof and pharmaceutically acceptable carriers. The invention also provides a preparation method and application of the combined medicament. The medicinal preparations are three-layer tablets so as to avoid interaction of the aliskiren and the telmisartan, improve the medicament stability and facilitate long-term storage. The composition preparations are used for treating medium and high hypertension patients and hypertension patients whose blood pressure cannot be fully controlled after being treated by angiotensin II receptor antagonists or renin inhibitors.

The invention discloses a medicine composite for treating and relieving high blood pressure and a preparation method thereof. The composite comprises 10-320mg of telmisartan and 1-20mg of felodipine slow-release preparation. The composite is used for treating patients with moderate and acute high blood pressure and patients whose blood pressure can not be adequately controlled after the high blood pressure is treated by an angiotensin II receptor antagonist or a calcium antagonist.

The invention provides a refining method for an enkephalin enzyme inhibitor and angiotensin II receptor antagonist eutectic compound. The refining method comprises the following steps that firstly, under the condition of minus 10-80 DEG C, an LCZ696 crude product is put into a good solvent and stirred to complete dissolution, wherein LCZ696 is the enkephalin enzyme inhibitor and angiotensin II receptor antagonist eutectic compound; secondly, the solution obtained in the first step is added with a poor solvent, crystallization and filtering are carried out, and a solid is obtained; thirdly, the solid obtained in the second step is dried to the constant weight, and an LCZ696 product is obtained. The refining method has the advantages that enkephalin enzyme inhibitor hydrolysis impurities and other impurities in the LCZ696 crude product can be effectively removed, the purity of the LCZ696 product can be improved, and thus the quality stability of LCZ696 can be ensured; in addition, the refining method is high in product yield and easy to implement.

The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions.

The invention relates to medicine field, and particularly relates to an angiotensin II receptor antagonist valsartan dispersible tablet and a preparation method thereof. The prescription of the product comprises pharmaceutical adjuvants acceptable in pharmacy like valsartan bulk drug, a filler, a disintegrant, an adhesive, flow aid, a lubricant, and corrigent, and the dispersible tablet is prepared by a wet granulation method. The valsartan bulk drug needs to be micronized, and the diameter 90 is less than 75mu m, preferably, the diameter 90 is less than 10mu m. The size distribution of the valsartan bulk drug directly affects the dispersibility of the dispersible tablet. The valsartan has polymorphy, different crystal forms of valsartan have different size distribution, and the dispersibility of the valsartan dispersible tablet is more different. The size distribution of the valsartan bulk drug is controlled by virtue of the micronization technology, the diameter 90 is less than 75mu m, preferably, when the diameter 90 is less than 10mu m, the difference of size distribution of different crystal forms of valsartan bulk drug is eliminated, the dispersibility of the valsartan dispersible tablet is improved obviously, the drug dissolution rate of the valsartan dispersible tablet is improved, and the product quality is controllable and is improved remarkably.